194 related articles for article (PubMed ID: 23160178)
1. Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene.
Burns TA; Subathra M; Signorelli P; Choi Y; Yang X; Wang Y; Villani M; Bhalla K; Zhou D; Luberto C
J Lipid Res; 2013 Mar; 54(3):794-805. PubMed ID: 23160178
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.
Li Z; Hailemariam TK; Zhou H; Li Y; Duckworth DC; Peake DA; Zhang Y; Kuo MS; Cao G; Jiang XC
Biochim Biophys Acta; 2007 Sep; 1771(9):1186-94. PubMed ID: 17616479
[TBL] [Abstract][Full Text] [Related]
3. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C?
Luberto C; Hannun YA
J Biol Chem; 1998 Jun; 273(23):14550-9. PubMed ID: 9603970
[TBL] [Abstract][Full Text] [Related]
4. Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.
Moorthi S; Burns TA; Yu GQ; Luberto C
FASEB J; 2018 Aug; 32(8):4270-4283. PubMed ID: 29533737
[TBL] [Abstract][Full Text] [Related]
5. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
6. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells.
Meng A; Luberto C; Meier P; Bai A; Yang X; Hannun YA; Zhou D
Exp Cell Res; 2004 Jan; 292(2):385-92. PubMed ID: 14697345
[TBL] [Abstract][Full Text] [Related]
7. Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy.
Barceló-Coblijn G; Martin ML; de Almeida RF; Noguera-Salvà MA; Marcilla-Etxenike A; Guardiola-Serrano F; Lüth A; Kleuser B; Halver JE; Escribá PV
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19569-74. PubMed ID: 22106271
[TBL] [Abstract][Full Text] [Related]
8. Anti-proliferative effects of tricyclodecan-9-yl-xanthogenate (D609) involve ceramide and cell cycle inhibition.
Gusain A; Hatcher JF; Adibhatla RM; Wesley UV; Dempsey RJ
Mol Neurobiol; 2012 Jun; 45(3):455-64. PubMed ID: 22415444
[TBL] [Abstract][Full Text] [Related]
9. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
12. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
13. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
Stella S; Tirrò E; Conte E; Stagno F; Di Raimondo F; Manzella L; Vigneri P
Mol Cancer Ther; 2013 Jun; 12(6):1085-98. PubMed ID: 23536723
[TBL] [Abstract][Full Text] [Related]
14. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
Nakamura S; Yokota D; Tan L; Nagata Y; Takemura T; Hirano I; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Int J Cancer; 2012 Mar; 130(5):1046-59. PubMed ID: 21400515
[TBL] [Abstract][Full Text] [Related]
16. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
17. Novel Interconnections in Lipid Metabolism Revealed by Overexpression of Sphingomyelin Synthase-1.
Deevska GM; Dotson PP; Karakashian AA; Isaac G; Wrona M; Kelly SB; Merrill AH; Nikolova-Karakashian MN
J Biol Chem; 2017 Mar; 292(12):5110-5122. PubMed ID: 28087695
[TBL] [Abstract][Full Text] [Related]
18. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
Baran Y; Salas A; Senkal CE; Gunduz U; Bielawski J; Obeid LM; Ogretmen B
J Biol Chem; 2007 Apr; 282(15):10922-34. PubMed ID: 17303574
[TBL] [Abstract][Full Text] [Related]
19. Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage.
Separovic D; Semaan L; Tarca AL; Awad Maitah MY; Hanada K; Bielawski J; Villani M; Luberto C
Exp Cell Res; 2008 May; 314(8):1860-8. PubMed ID: 18374917
[TBL] [Abstract][Full Text] [Related]
20. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Nimmanapalli R; Porosnicu M; Nguyen D; Worthington E; O'Bryan E; Perkins C; Bhalla K
Clin Cancer Res; 2001 Feb; 7(2):350-7. PubMed ID: 11234890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
